{"database": "openregs", "table": "documents", "rows": [["FDA-2023-N-2177-0087", "FDA", "FDA-2023-N-2177", "Reference 44 - Letter from D. Bruce Burlington M.D. Director FDA-CDRH to Jeffrey N. Gibbs Esq. Hyman Phelps  McNamara P.C. RE: Medical Devices; Laboratory Developed Tests", "Supporting & Related Material", "Background Material", "2023-10-04T04:00:00Z", 2023, 10, null, null, "2023-10-05T16:03:05Z", null, 0, 0, "09000064860259dd"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "primary_key_values": ["FDA-2023-N-2177-0087"], "units": {}, "query_ms": 0.503488932736218, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}